Study of Velcade and Thalidomide in Patients With Myelodysplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-30

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

NCT02312102

Myelodysplastic Syndrome Acute Myeloid Leukemia

COMPLETED PHASE1

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

NCT00287872

Multiple Myeloma

COMPLETED PHASE2

Bortezomib in Treating Patients With Myelodysplastic Syndromes

NCT00262873

Myelodysplastic Syndromes

COMPLETED PHASE2

Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

NCT00910897

Multiple Myeloma

UNKNOWN PHASE3

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00818649

Leukemia Myelodysplastic Syndrome

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Initial studies using Velcade in myelodysplasia with early results demonstrating that 35% had a partial response and 25% had stable disease. The combination of Velcade and thalidomide has been studied in patients with multiple myeloma, but not in patients with myelodysplasia. The CRR in the MM patients was 22%, with a good safety profile.

This is a phase 1, prospective, open-label, dose escalation study to evaluate the DLT and MTD of velcade with given in combination with thalidomide in patients with myelodysplasia. Treatment will be given as an outpatient. Patients will receive 4 days of Velcade (days 1, 4, 8, 11) and 21 days of thalidomide 50 mg/day for each 21 day cycle. There will be 3 cohorts of 3-6 patients each, plus 10 additional patients. The tree dose levels ill be 0.7, 1.0 and 1.3 mg/m2. Patients may continue to be treated up to 6 cycles. Cycles 2-6 will start within 2 weeks of completion of the previous cycle. Disease response will be evaluated after cycle 3 and 6.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bortezomib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Myelodysplastic syndrome with a IPSS score of 0.5 or greater
* May have had prior chemo/radiotherapy for another malignancy or myelodysplasia
* ECOG performance status of 0-2
* Life expectancy greater than 3 months
* Total bilirubin \</+ 2xULN
* ALT and AST \</+ 3xULN
* Calculated creatinine clearance \> 30 ml/min
* Use of appropriate method of contraception during the study
* ANC \> 0.5 x 10(9)
* Platelet count \> 30 x 10(9)
* Consideration of treatment with 5 azacytidine is encouraged by not required

Exclusion Criteria

* Ejection fraction \< 40%
* myocardial infarction within 6 months of enrollment of New York Heart Association Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
* Women who are pregnant or breast-feeding
* Major surgery within 4 weeks prior to enrollment
* \>/= grade 2 peripheral neuropathy within 14 days prior to enrollment
* Uncontrolled intercurrent illness
* Serious medical or psychiatric illness that could potentially interfere with the completion of treatment
* Hypersensitivity to bortezomib, boron, or mannitol
* Received an investigational drug within 14 days of enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No